Diabetes Technology Meeting 2023.

Diabetes Technology Society hosted its annual Diabetes Technology Meeting from November 1 to November 4, 2023. Meeting topics included digital health; metrics of glycemia; the integration of glucose and insulin data into the electronic health record; technologies for insulin pumps, blood glucose monitors, and continuous glucose monitors; diabetes drugs and analytes; skin physiology; regulation of diabetes devices and drugs; and data science, artificial intelligence, and machine learning. A live demonstration of a personalized carbohydrate dispenser for people with diabetes was presented.
Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JHJ was also a speaker for Eli Lilly, Boehringer Ingelheim, Nordic Infucare, Novo Nordisk, Sanofi, and an advisory board member for Abbott, Eli Lilly, and Medtronic. DK has received research support from Abbott Diabetes Care and has been a Consultant to Sanofi, Better Therapeutics and Abbott Diagnostics. EC is an advisory board member and consultant for Novo Nordisk, Eli Lilly, Adocia, MannKind, Lexicon, Arecor. EC was also a speaker for Novo Nordisk. JP reports consultancy fees from Medtronic. NS is an employee of Medcrypt. DM is a consultant for Capillary Biomedical and a shareholder in Halozyme Therapeutics. HKA received research grant support through University of Colorado from Medtronic, Tandem Diabetes, Eli Lilly, Mannkind, Dexcom and consultation fees through University of Colorado from Tandem Diabetes, Medtronic and Dexcom. CJL has received research support by the NIDDK and Helmsley Foundation and industry support paid to the Icahn School of Medicine at Mount Sinai from Abbott Diabetes, Dexcom, Insulet, Novo Nordisk, Mannkind, Senseonics, and Tandem. CJL has received consulting fees from Eli Lilly, and Dexcom outside of this work. RB is a shareholder of Biomeris s.r.l. and Engenome s.r.l. EKS was partially supported by the VA MERIT award (#1I01CX001825) and CSP #2002 from the US Department of Veterans Affairs. EKS has received unrestricted research support from Dexcom and Tandem (to Baltimore VA Medical Center and to University of Maryland) for the conduction of clinical trials. EKS has received fees from the Medscape and the Endocrine Society (ESAP). BN is serving as a consultant for BioSensics LLC. JJS is a consultant for Lifescan Diabetes Institute. DCK is a consultant for Afon, Better Therapeutics, Integrity, Lifecare, Nevro, Novo, and Thirdwayv. TT, REA, AYD, AD, KYC, SS, AHBW, JGC have nothing to disclose.